Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Joost W. Geenen; Ekaterina V. Baranova; Folkert W. Asselbergs; Anthonius de Boer; Rick A. Vreman; Colin Na Palmer; Anke H. Maitland-van der Zee; Anke M. Hövels

doi:https://doi.org/10.2217/pgs-2017-0063

Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Joost W. Geenen, Ekaterina V. Baranova, Folkert W. Asselbergs, Anthonius de Boer, Rick A. Vreman, Colin Na Palmer, Anke H. Maitland-van der Zee, Anke M. Hövels

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. Materials & methods: A decision tree was used. Results: With a willingness-to-pay threshold of (sic)20,000 and (sic)80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of (sic)1.30 and (sic)1.95, respectively. When only genotyping high-risk populations, the maximum test price would be (sic)5.03 and (sic)7.55, respectively. Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention

Original language	English
Pages (from-to)	1143-1153
Journal	Pharmacogenomics
Volume	18
Issue number	12
DOIs	https://doi.org/10.2217/pgs-2017-0063
Publication status	Published - 2017

Access to Document

https://doi.org/10.2217/pgs-2017-0063

Cite this

@article{fe322394a1cb41b292232687c757bef6,

title = "Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs",

abstract = "Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. Materials & methods: A decision tree was used. Results: With a willingness-to-pay threshold of (sic)20,000 and (sic)80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of (sic)1.30 and (sic)1.95, respectively. When only genotyping high-risk populations, the maximum test price would be (sic)5.03 and (sic)7.55, respectively. Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention",

author = "Geenen, {Joost W.} and Baranova, {Ekaterina V.} and Asselbergs, {Folkert W.} and {de Boer}, Anthonius and Vreman, {Rick A.} and Palmer, {Colin Na} and {Maitland-van der Zee}, {Anke H.} and H{\"o}vels, {Anke M.}",

year = "2017",

doi = "https://doi.org/10.2217/pgs-2017-0063",

language = "English",

volume = "18",

pages = "1143--1153",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "12",

}

TY - JOUR

T1 - Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

AU - Geenen, Joost W.

AU - Baranova, Ekaterina V.

AU - Asselbergs, Folkert W.

AU - de Boer, Anthonius

AU - Vreman, Rick A.

AU - Palmer, Colin Na

AU - Maitland-van der Zee, Anke H.

AU - Hövels, Anke M.

PY - 2017

Y1 - 2017

N2 - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. Materials & methods: A decision tree was used. Results: With a willingness-to-pay threshold of (sic)20,000 and (sic)80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of (sic)1.30 and (sic)1.95, respectively. When only genotyping high-risk populations, the maximum test price would be (sic)5.03 and (sic)7.55, respectively. Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention

AB - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations. Materials & methods: A decision tree was used. Results: With a willingness-to-pay threshold of (sic)20,000 and (sic)80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of (sic)1.30 and (sic)1.95, respectively. When only genotyping high-risk populations, the maximum test price would be (sic)5.03 and (sic)7.55, respectively. Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention

U2 - https://doi.org/10.2217/pgs-2017-0063

DO - https://doi.org/10.2217/pgs-2017-0063

M3 - Article

C2 - 28745583

SN - 1462-2416

VL - 18

SP - 1143

EP - 1153

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 12

ER -